We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

18 hedge funds and large institutions have $25.7M invested in Tonix Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

18% less funds holding

Funds holding: 22 → 18 (-4)

41% less capital invested

Capital invested by funds: $43.7M → $25.7M (-$17.9M)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
18
Holders Change
-4
Holders Change %
-18.18%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.99M
2
BlackRock
BlackRock
New York
+$918K
3
State Street
State Street
Massachusetts
+$306K
4
CM
Crestline Management
Texas
+$153K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$153K

Top Sellers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$3.21M
2
Prudential Financial
Prudential Financial
New Jersey
-$1.68M
3
AQR Capital Management
AQR Capital Management
Connecticut
-$366K
4
AFM
Anson Funds Management
Texas
-$309K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$306K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$7.92M +$918K +6 +13%
Renaissance Technologies
2
Renaissance Technologies
New York
$4.42M +$1.99M +13 +76%
Vanguard Group
3
Vanguard Group
Pennsylvania
$4.21M -$306K -2 -6%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$1.75M +$153K +1 +9%
State Street
5
State Street
Massachusetts
$1.71M +$306K +2 +20%
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$1.15M -$3.21M -21 -72%
Northern Trust
7
Northern Trust
Illinois
$952K – – –
GCP
8
GSA Capital Partners
United Kingdom
$435K – – –
Bank of America
9
Bank of America
North Carolina
$327K -$153K -1 -33%
N
10
Nuveen
North Carolina
$315K -$153K -1 -33%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$305K – – –
Charles Schwab
12
Charles Schwab
California
$288K – – –
Osaic Holdings
13
Osaic Holdings
Arizona
$228K – – –
Two Sigma Advisers
14
Two Sigma Advisers
New York
$182K – – –
Morgan Stanley
15
Morgan Stanley
New York
$125K – – –
AA
16
ALPS Advisors
Colorado
$117K – – –
Goldman Sachs
17
Goldman Sachs
New York
$98K – – –
RhumbLine Advisers
18
RhumbLine Advisers
Massachusetts
$86K – – –
CM
19
Crestline Management
Texas
$82K +$153K +1 New
EDRH
20
Edmond de Rothschild Holding
Switzerland
$69K – – –
JP Morgan Chase
21
JP Morgan Chase
New York
$66K – – –
UBS Group
22
UBS Group
Switzerland
$58K -$153K -1 Closed
AIG
23
American International Group
New York
$57K – – –
Deutsche Bank
24
Deutsche Bank
Germany
$55K – – –
Citadel Advisors
25
Citadel Advisors
Florida
$54K – – –
1
2 3 4

TNXP Hedge Fund Activity: Q1 2022 in Review

18 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q1 2022, worth a combined $25.7M — down 41% from $43.7M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of TNXP and 1 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 4 added.

The largest buyer was Renaissance Technologies, adding an estimated $1.99M. The largest seller was D.E. Shaw & Co, cutting an estimated $3.21M.

  • 18 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q1 2022, down from 22 in Q4 2021.
  • Funds reported $25.7M of Tonix Pharmaceuticals stock for Q1 2022, down 41% quarter-over-quarter.
  • 1 fund opened new Tonix Pharmaceuticals positions in Q1 2022 and 5 closed out, a net change of -4 holders.
  • The largest Tonix Pharmaceuticals buyer in Q1 2022 was Renaissance Technologies, an estimated $1.99M added.
  • The largest Tonix Pharmaceuticals seller in Q1 2022 was D.E. Shaw & Co, an estimated $3.21M sold.

Based on aggregated 13F filings for Q1 2022.